GENFIT
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. Their pioneering research is based on a strong heritage, stemming from in-house knowledge and their desire to strive for excellence. Their drug discovery efforts are based on selecting specific nuclear receptors as tar... gets and utilizing rational drug design to optimize their drug candidates. This strong skill base associated to their scientific and clinical expertise, translational disease-driven approach and strong bioinformatics capabilities, have allowed us to build a solid scientific platform enabling us to discover and develop their drug candidates and diagnostic tools. Professor Bart Staels, a world-renowned expert in nuclear receptors, co-founded GENFIT and has played a key role in shaping their company’s expertise over the years. Today, he sits as chair of the Scientific Advisory Board, lending decades of experience and essential know-how, supporting their role as an innovative leader in the discovery of solutions for the metabolic field.
GENFIT
Industry:
Biopharma Biotechnology Health Care
Founded:
1999-09-01
Address:
Loos, Nord-Pas-de-Calais, France
Country:
France
Website Url:
http://www.genfit.com
Total Employee:
101+
Status:
Active
Contact:
33320164001
Email Addresses:
[email protected]
Total Funding:
93.69 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network
Similar Organizations
Alpha Biopharma
Alpha Biophama is a clinical stage biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Mereo Biopharma
Mereo is a new UK-based speciality biopharmaceutical company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Official Site Inspections
http://www.genfit.com Semrush global rank: 6.12 M Semrush visits lastest month: 1.32 K
- Host name: 107.154.238.20.ip.incapdns.net
- IP address: 107.154.238.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "GENFIT"
About - Genfit
Listing of GENFIT on the Alternext Market of Euronext Paris and transferred in 2014 onto the Euronext Market in Paris (compartment B – ISIN: FR0004163111) ... 3 National organization …See details»
GENFIT - Crunchbase Company Profile & Funding
Professor Bart Staels, a world-renowned expert in nuclear receptors, co-founded GENFIT and has played a key role in shaping their company’s expertise over …See details»
GENFIT career: recruitment in biopharmaceutical | GENFIT
GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre …See details»
Genfit Company Profile - Office Locations, Competitors, Revenue …
Genfit has 5 employees across 2 locations and €28.57 m in annual revenue in FY 2023. See insights on Genfit including office locations, competitors, revenue, financials, executives, …See details»
GENFIT - The Org
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases …See details»
Financial and extra-financial reports - GENFIT
Dec 31, 2024 GENFIT's latest financial reports & financial results. GENFIT Headquarters Parc Eurasanté 885, Avenue Eugène Avinée 59120 Loos France GENFIT Corp 45 Propect St. …See details»
Genfit S.A. (GNFTF) Company Profile & Overview - Stock Analysis
Dec 27, 2024 Genfit Company Description Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver …See details»
Homepage - Genfit
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update Cash and cash equivalents totaled €81.8 million as of December 31, 2024. Completion in early 2025 of: (i) a non-dilutive royalty financing …See details»
GENFIT: Publication of the 2025 Extra-Financial Performance
20 hours ago ABOUT GENFIT. GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs …See details»
Homepage - Genfit
C’est le premier médicament développé en interne par GENFIT à obtenir l’approbation de la FDA américaine, une étape historique pour notre entreprise. Ipsen est désormais responsable des …See details»
GENFIT: Publication of the 2025 Extra-Financial Performance
1 day ago Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to …See details»
| GENFIT
Read more about GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval GENFIT …See details»
Therapeutic Areas - Genfit
GENFIT is a company that specializes in the discovery and development of drugs that target rare and life-threatening liver diseases with high unmet medical needs and is a world leader in …See details»
GENFIT Announces Publication of the 2024 Universal Registration ...
Apr 29, 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company …See details»
Genfit (LON:0QT6) Company Profile & Description - Stock Analysis
May 7, 2025 Genfit Company Description Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver …See details»
Contact - Genfit
GENFIT Headquarters Parc Eurasanté885, Avenue Eugène Avinée59120 LoosFrance+33 (0)3 20 16 40 00 GENFIT Corp 45 Propect St. Suite 214CambridgeMA. Go to main navigation Go to …See details»
GENFIT Announces Publication of the 2024 Universal Registration ...
Apr 29, 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company …See details»
GENFIT Announces Publication of the 2024 Universal
Apr 29, 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company …See details»
Expertise - Genfit
Liver Diseases. At GENFIT, we take pride in our longstanding expertise in the field of liver diseases. We have established ourselves as a leader in understanding and developing …See details»
GENFIT: May 22, 2024 Combined Shareholders Meeting Results
May 22, 2024 Quorum of 27.25% on first convening; allowing approval of all the resolutions ; Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2024 …See details»